Regeneron Up 43.3% Over Six Months, Beats Q4 Revenue Despite Eylea Decline
Regeneron shares have gained 43.3% over six months versus a 26.3% industry rise, and in Q4 the company beat earnings and revenues with total sales rising despite an Eylea volume decline. Drivers include strong uptake of Eylea HD, growth in Dupixent, label expansions for Libtayo and FDA approval of Lynozyfic for relapsed or refractory multiple myeloma.
1. Stock Performance and Q4 Results
Regeneron shares rose 43.3% over the past six months compared with a 26.3% gain in the Medical - Biomedical and Genetics industry. In the fourth quarter the company beat both earnings and revenue estimates, reporting overall sales growth despite a year-over-year decline in volumes of its flagship Eylea therapy.
2. Key Growth Drivers and Pipeline Updates
The strong initial uptake of Eylea HD is offsetting declines in base Eylea sales, while Dupixent continues to expand across its approved indications. Label expansions for the oncology antibody Libtayo are advancing its cancer franchise, and the FDA’s approval of Lynozyfic for relapsed or refractory multiple myeloma adds a new high-value therapy to Regeneron’s pipeline.